Overcoming BCMA loss in myeloma cells скачать в хорошем качестве

Overcoming BCMA loss in myeloma cells

While BCMA is a highly efficacious target for multiple myeloma treatments, evidence is mounting that a proportion of patients treated with BCMA-directed agents will develop irreversible resistance to these therapies, attributable to biallelic BCMA loss. Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses alternative targets and therapies being developed against them. For example, talquetamab is a first-in-class investigational bispecific antibody targeting GPRCD5 and CD3, and cevostamab is a novel FcRH5xCD3 bispecific antibody shown to be highly active in early clinical trials. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.